covid-19 |
2 |
drug repurposing |
2 |
network biology |
2 |
network pharmacology |
2 |
adolescent |
1 |
adult |
1 |
aged |
1 |
all-cause mortality |
1 |
asthma |
1 |
attention deficit hyperactivity disorder |
1 |
breast tumor |
1 |
cause-specific mortality |
1 |
dirichlet-laplace |
1 |
dose finding |
1 |
drug combination |
1 |
female |
1 |
genetic risk stratification |
1 |
genome-wide association studies |
1 |
global-local shrinkage prior |
1 |
hyperparameter tuning |
1 |
lifestyle modification |
1 |
maximum tolerated dose |
1 |
non-parametric method |
1 |
paracetamol |
1 |
phase i trial design |
1 |
polygenic risk scores |
1 |
posterior consistency |
1 |
posterior credible region |
1 |
variable selection |
1 |